Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 125
2021 157
2022 109
2023 47
2024 34
2025 30
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

446 results

Results by year

Filters applied: . Clear all
Page 1
Tocilizumab and COVID-19: Timing of Administration and Efficacy.
Abidi E, El Nekidy WS, Alefishat E, Rahman N, Petroianu GA, El-Lababidi R, Mallat J. Abidi E, et al. Front Pharmacol. 2022 Feb 18;13:825749. doi: 10.3389/fphar.2022.825749. eCollection 2022. Front Pharmacol. 2022. PMID: 35250575 Free PMC article. Review.
Elevated concentrations of interleukin-6 have been demonstrated to be an important key factor in COVID-19 host immune impairment. It represents an important prognostic factor of harm associated with COVID-19 infection by stimulating a vigorous proinfla …
Elevated concentrations of interleukin-6 have been demonstrated to be an important key factor in COVID-19 host immune impairme …
Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.
Aziz M, Haghbin H, Abu Sitta E, Nawras Y, Fatima R, Sharma S, Lee-Smith W, Duggan J, Kammeyer JA, Hanrahan J, Assaly R. Aziz M, et al. J Med Virol. 2021 Mar;93(3):1620-1630. doi: 10.1002/jmv.26509. Epub 2020 Sep 28. J Med Virol. 2021. PMID: 32918755
The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin-6 (IL-6) receptor, in patients with coronavirus disease-2019 (COVID-19) patients has led to conflicting results. We performed a systematic review and meta-analysis to com …
The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin-6 (IL-6) receptor, in patients with coronavirus …
Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.
Rezaei Tolzali MM, Noori M, Shokri P, Rahmani S, Khanzadeh S, Nejadghaderi SA, Fazlollahi A, Sullman MJM, Singh K, Kolahi AA, Arshi S, Safiri S. Rezaei Tolzali MM, et al. Rev Med Virol. 2022 Nov;32(6):e2388. doi: 10.1002/rmv.2388. Epub 2022 Aug 27. Rev Med Virol. 2022. PMID: 36029180 Free PMC article.
Tocilizumab is an interleukin (IL)-6 receptor inhibitor that has been proposed as a therapeutic agent for treating coronavirus disease 2019 (COVID-19). ...These databases were searched up to 30 September 2021, using the following keywords: 'SARS …
Tocilizumab is an interleukin (IL)-6 receptor inhibitor that has been proposed as a therapeutic agent for treating coronavirus …
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, Altannir Y, Al-Tannir M, Tleyjeh R, Hassett L, Kashour T. Tleyjeh IM, et al. Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5. Clin Microbiol Infect. 2021. PMID: 33161150 Free PMC article.
OBJECTIVES: Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our objective was to perform a living systematic review of the literature concerning …
OBJECTIVES: Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated with multiorgan damage and death in severe …
Tocilizumab and COVID-19: Timing of administration assessment.
Richier Q, Jachiet V, Bonnemains V, Plaçais L, Abisror N, Garnier M, Pacanowski J, Dhote R, Hinchschberger O, Michel M, Bienvenu B, Comarmond C, Lacombe K, Mekinian A. Richier Q, et al. Infect Dis Now. 2022 Feb;52(1):31-34. doi: 10.1016/j.idnow.2021.06.304. Epub 2021 Jun 29. Infect Dis Now. 2022. PMID: 34198000 Free PMC article.
Recent evidence showed greater efficacy of tocilizumab (TCZ) in the subgroups of COVID-19 patients who presented with symptoms for less than 7 days and in those only receiving oxygen. ...We showed no association between the timing of injection after sy …
Recent evidence showed greater efficacy of tocilizumab (TCZ) in the subgroups of COVID-19 patients who presented …
Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review.
Chamlagain R, Shah S, Sharma Paudel B, Dhital R, Kandel B. Chamlagain R, et al. Interdiscip Perspect Infect Dis. 2021 Oct 22;2021:8903435. doi: 10.1155/2021/8903435. eCollection 2021. Interdiscip Perspect Infect Dis. 2021. PMID: 34721573 Free PMC article. Review.
BACKGROUND: It has been found that there is overactivation of immune response in patients with COVID-19. Several studies are going on to assess the role of immunomodulation. IL-6 antibodies such as tocilizumab have been found to have efficacy in the tr …
BACKGROUND: It has been found that there is overactivation of immune response in patients with COVID-19. Several studies are g …
Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial.
Gholinataj Jelodar M, Rafieian S, Saghafi F, Hadad Zedegan N, Birjandi B, Rafieian S, Allah Dini A, Dehghanpour H, Khalaj F, Zare S, Dehghan Chenari H, Hajimaghsoudi M, Mojtaba Sohrevardi S, Mirzaei S, Jamialahmadi T, Atkin SL, Sahebkar A. Gholinataj Jelodar M, et al. Int Immunopharmacol. 2023 Feb;115:109623. doi: 10.1016/j.intimp.2022.109623. Epub 2022 Dec 21. Int Immunopharmacol. 2023. PMID: 36577157 Free PMC article. Review.
BACKGROUND: This study sought to evaluate and compare the effectiveness of plasmapheresis, Tocilizumab, and Tocilizumab with plasmapheresis treatment on the removal of inflammatory cytokines and improvement clinically of patients with severe COVID-19 i …
BACKGROUND: This study sought to evaluate and compare the effectiveness of plasmapheresis, Tocilizumab, and Tocilizumab with p …
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
Tleyjeh IM, Kashour Z, Riaz M, Hassett L, Veiga VC, Kashour T. Tleyjeh IM, et al. Clin Microbiol Infect. 2021 Aug;27(8):1076-1082. doi: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27. Clin Microbiol Infect. 2021. PMID: 33915284 Free PMC article.
OBJECTIVES: Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our objective was to update the data in a living systematic review of the literature …
OBJECTIVES: Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated with multiorgan damage and death in severe …
Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.
Piscoya A, Parra Del Riego A, Cerna-Viacava R, Rocco J, Roman YM, Escobedo AA, Pasupuleti V, White CM, Hernandez AV. Piscoya A, et al. PLoS One. 2022 Jun 3;17(6):e0269368. doi: 10.1371/journal.pone.0269368. eCollection 2022. PLoS One. 2022. PMID: 35657993 Free PMC article.
INTRODUCTION: We systematically assessed benefits and harms of tocilizumab (TCZ), which is an antibody blocking IL-6 receptors, in hospitalized COVID-19 patients. ...TCZ has a potential role in the treatment of hospitalized COVID-19 patients....
INTRODUCTION: We systematically assessed benefits and harms of tocilizumab (TCZ), which is an antibody blocking IL-6 receptors, in ho …
Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis.
Zhang J, Fan X, Zhang X, Jiang F, Wu Y, Yang B, Li X, Liu D. Zhang J, et al. Front Pharmacol. 2023 Nov 22;14:1293331. doi: 10.3389/fphar.2023.1293331. eCollection 2023. Front Pharmacol. 2023. PMID: 38074144 Free PMC article.
Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19 patients with hyperinflammatory response; however, there is a lack of systematic review directly evaluating their efficacy and safety. Objective: This review was c …
Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19 patients with hyperinflammator …
446 results